Australian Clinical Labs (ACL) Stock Overview
Provides pathology diagnostic services in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
ACL Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Australian Clinical Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.96 |
| 52 Week High | AU$2.98 |
| 52 Week Low | AU$1.83 |
| Beta | 0.81 |
| 1 Month Change | 32.74% |
| 3 Month Change | 50.25% |
| 1 Year Change | 17.93% |
| 3 Year Change | 3.50% |
| 5 Year Change | -33.33% |
| Change since IPO | -13.45% |
Recent News & Updates
Recent updates
Narrative Update • Aug 19
ACL: CEO Transition And Updated Assumptions Will Shape Fairly Valued Outlook
Analysts have nudged their valuation higher for Australian Clinical Labs, lifting the indicated fair value from A$2.58 to A$2.88. This reflects refreshed assumptions on discount rate, revenue growth, profit margins and future P/E.
Narrative Update • Jun 12
ACL: New CEO Appointment Will Support Undervalued Share Price
Analysts have kept their A$ price target for Australian Clinical Labs unchanged, supported by updated assumptions around a higher discount rate, slightly adjusted revenue growth expectations, modestly revised profit margin forecasts, and a broadly consistent future P/E outlook. What's in the News Australian Clinical Labs appointed Greg Horan as Group CEO, with his role commencing as Group CEO elect on June 1, 2026, and transitioning to full Group CEO on August 31, 2026, when current Group CEO and Executive Director Melinda McGrath steps down after 10 years.Narrative Update • May 29
ACL: New CEO Appointment And Index Inclusion Will Support Future Upside
Analysts have slightly reset their price target for Australian Clinical Labs to A$2.58, reflecting updates to assumptions around the discount rate and future P/E multiples, while keeping fair value estimates broadly unchanged. What's in the News Australian Clinical Labs appointed Greg Horan as Group CEO, with Horan joining as Group CEO elect on 1 June 2026 and formally taking over on 31 August 2026 when current Group CEO and Executive Director Melinda McGrath steps down after 10 years in the role (Key Developments).Narrative Update • May 05
ACL: Index Inclusion And Franked Dividend Will Support Undervalued Share Price
Analysts have trimmed their price target for Australian Clinical Labs slightly to A$3.48 from A$3.50, reflecting updated assumptions around revenue growth, profit margins, the discount rate and future P/E multiples. What's in the News Australian Clinical Labs has been added to the S&P/ASX Emerging Companies Index, placing the stock in a broader benchmark followed by many Australian equity investors (Key Developments).Narrative Update • Apr 20
ACL: Index Inclusion And Dividend Policy Will Support Future Share Price Upside
Analysts have reduced their price target for Australian Clinical Labs to A$2.58 from A$3.37, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Australian Clinical Labs Limited has been added to the S&P/ASX Emerging Companies Index, reflecting its inclusion in this benchmark group of smaller listed companies (Key Developments).
Narrative Update • Apr 05
ACL: Index Inclusion And Dividend Settings Will Shape A Balanced Outlook
Analysts have trimmed their price target on Australian Clinical Labs to A$2.20 from A$2.40, citing slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, partly offset by adjusted profit margin expectations. What's in the News Australian Clinical Labs Limited (ASX:ACL) is being added to the S&P/ASX Emerging Companies Index, which can increase visibility among index and fund investors (Index Constituent Adds).Narrative Update • Mar 22
ACL: Future Dividend Visibility Will Support Confidence In Undervalued Share Price
Analysts have trimmed their price target on Australian Clinical Labs from A$3.85 to A$3.50, citing updated assumptions that include a higher discount rate, a lower revenue growth outlook, a slightly higher profit margin and a modestly reduced future P/E multiple. What's in the News The Board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025, providing clearer visibility on near term cash returns (Key Developments).Narrative Update • Mar 07
ACL: Dividend Timeline And Updated Assumptions Will Shape A Measured Outlook
Analysts have nudged their price target for Australian Clinical Labs higher to A$2.40, reflecting updated assumptions around revenue growth, profit margins, the discount rate and future P/E that slightly increase their view of fair value from A$2.30. What's in the News The board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025, indicating a cash return to shareholders for that period (Key Developments).Narrative Update • Feb 21
ACL: Dividend Timeline And Revised Assumptions Will Guide A Balanced Outlook
Analysts have reduced their price target on Australian Clinical Labs by A$0.50 to A$2.30, citing updated assumptions around revenue growth, profit margin, discount rate and future P/E multiples. What's in the News The board has declared a fully franked interim dividend of A$0.0375 per share for the six months ending 31 December 2025 (Key Developments).Narrative Update • Feb 07
ACL: Updated Assumptions Will Support Confidence In Undervalued Share Price
Analysts have revised their price target on Australian Clinical Labs to A$3.85. The update reflects slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E, while keeping fair value unchanged at A$3.85.Narrative Update • Jan 24
ACL: Updated Discount Rate And Margins Will Shape A Measured Outlook
Analysts have trimmed their price target for Australian Clinical Labs to A$2.80 from A$2.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together point to a slightly more cautious valuation outlook. Valuation Changes Fair Value Estimate: Trimmed slightly from A$2.90 to A$2.80, reflecting a modestly lower central valuation point.Narrative Update • Jan 09
ACL: Share Buyback Plan Will Support Future Share Price Upside
Analysts have trimmed their price target for Australian Clinical Labs to about A$3.37 from A$3.40, citing slightly softer assumptions for revenue growth and profit margins, while keeping the assumed future P/E multiple broadly unchanged. What's in the News The Board of Directors authorized a share buyback plan on October 23, 2025, signaling an intention to return capital to shareholders over time (Key Developments).Narrative Update • Dec 15
ACL: Share Buyback And Cyber Penalty Resolution Will Support Stronger Outlook
Narrative Update on Australian Clinical Labs Analysts have trimmed their price target on Australian Clinical Labs from approximately A$4.73 to around A$3.85. This reflects slightly higher perceived risk, more moderate valuation multiples, and only modest upgrades to long term growth and margin assumptions.Narrative Update • Nov 30
ACL: Share Buyback Program Will Drive Shareholder Value Over The Next Year
Analysts have reaffirmed their price target for Australian Clinical Labs at $3.40, citing stable financial forecasts and consistent assumptions for discount rate, revenue growth, profit margin, and future price-earnings ratio. What's in the News The Board of Directors authorized a buyback plan on October 23, 2025 (Key Developments).Narrative Update • Nov 16
ACL: Share Buyback Plan And Acquisitions Will Drive Future Upside
Analysts have maintained their price target for Australian Clinical Labs at $3.40. They cite steady expectations for profit margins and revenue growth, even with a slight increase in the discount rate.Narrative Update • Nov 02
ACL: Share Buyback And Acquisition Plans Will Drive Strong Shareholder Returns
Analysts have revised their price target for Australian Clinical Labs slightly downward to $3.40. This adjustment is due to marginally lower expectations for revenue growth and future earnings multiples.Narrative Update • Oct 18
AI And Laboratory Automation Will Advance Personalized Testing
Analysts have lowered their price target for Australian Clinical Labs from $3.60 to $3.40. They cite adjustments to their revenue growth forecasts and a slightly higher discount rate in their valuation model.Analysis Article • Mar 02
Australian Clinical Labs Limited Just Missed Earnings - But Analysts Have Updated Their Models
It's been a mediocre week for Australian Clinical Labs Limited ( ASX:ACL ) shareholders, with the stock dropping 16% to...
New Narrative • Feb 09
Operational Improvements And New Genomic Tests Aim To Improve Future Outlook
Improving collection centers and digital transformations are set to enhance operational efficiency, boosting profit margins and supporting revenue growth.Analysis Article • Sep 03
Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge
Australian Clinical Labs Limited ( ASX:ACL ) shares have continued their recent momentum with a 29% gain in the last...Analysis Article • Sep 02
Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?
Australian Clinical Labs Limited ( ASX:ACL ), might not be a large cap stock, but it led the ASX gainers with a...Analysis Article • Jun 20
We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 21
Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Key Insights The projected fair value for Australian Clinical Labs is AU$5.01 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Dec 08
Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
While Australian Clinical Labs Limited ( ASX:ACL ) might not be the most widely known stock at the moment, it saw a...Analysis Article • Aug 14
Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Shareholder Returns
| ACL | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | 26.0% | -2.1% | -0.6% |
| 1Y | 17.9% | -1.7% | 0.04% |
Return vs Industry: ACL exceeded the Australian Healthcare industry which returned -1.7% over the past year.
Return vs Market: ACL exceeded the Australian Market which returned 0% over the past year.
Price Volatility
| ACL volatility | |
|---|---|
| ACL Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 5.3% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.9% |
Stable Share Price: ACL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ACL's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 4,500 | Melinda McGrath | www.clinicallabs.com.au |
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers cardiac testing, gastroenterology, haematology, chemical pathology, antenatal testing, serology and microbiology, cervical screening, commercial drug and alcohol testing, STI Testing, veterinary pathology, molecular cancer services, clinical trials pathology, advanced genetic testing, functional pathology, histopathology and cytopathology, CPD education programs for clinicians, and allergy and immunology services. It also provides workplace services, environmental screening, and clinical trial services.
Australian Clinical Labs Limited Fundamentals Summary
| ACL fundamental statistics | |
|---|---|
| Market cap | AU$547.74m |
| Earnings (TTM) | AU$23.71m |
| Revenue (TTM) | AU$736.15m |
23.1x
P/E Ratio0.7x
P/S RatioIs ACL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACL income statement (TTM) | |
|---|---|
| Revenue | AU$736.15m |
| Cost of Revenue | AU$465.14m |
| Gross Profit | AU$271.01m |
| Other Expenses | AU$247.30m |
| Earnings | AU$23.71m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 36.81% |
| Net Profit Margin | 3.22% |
| Debt/Equity Ratio | 41.4% |
How did ACL perform over the long term?
See historical performance and comparisonDividends
4.4%
Current Dividend Yield105%
Payout RatioDoes ACL pay a reliable dividends?
See ACL dividend history and benchmarks| Australian Clinical Labs dividend dates | |
|---|---|
| Ex Dividend Date | Sep 02 2026 |
| Dividend Pay Date | Sep 23 2026 |
| Days until Ex dividend | 10 days |
| Days until Dividend pay date | 31 days |
Does ACL pay a reliable dividends?
See ACL dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/22 21:11 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Australian Clinical Labs Limited is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lyanne Harrison | BofA Global Research |
| Shane Storey | Canaccord Genuity |
| Citi Research | Citigroup Inc |